Sustained low‐dose interleukin‐2 therapy alleviates pathogenic humoral immunity via elevating the Tf...
Sustained low‐dose interleukin‐2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus
About this item
Full title
Author / Creator
Liang, Kaili , He, Jing , Wei, Yunbo , Zeng, Qunxiong , Gong, Dongcheng , Qin, Jiahuan , Ding, Huihua , Chen, Zhian , Zhou, Ping , Niu, Peng , Chen, Qian , Ding, Chenguang , Lu, Liangjing , Chen, Xiao‐Xiang , Li, Zhanguo , Shen, Nan , Yu, Di and Deng, Jun
Publisher
Australia: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Australia: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Objectives
Low‐dose interleukin‐2 (IL‐2) has shown promising clinical benefits in the treatment of systemic lupus erythematosus (SLE), but how this therapy alleviates pathogenic humoral immunity remains not well understood. The dilemma is that IL‐2 can suppress both follicular helper and regulatory T (Tfh and Tfr) cells, which counteract each ot...
Alternative Titles
Full title
Sustained low‐dose interleukin‐2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d95ff37cc3204c5d896e891664daae71
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d95ff37cc3204c5d896e891664daae71
Other Identifiers
ISSN
2050-0068
E-ISSN
2050-0068
DOI
10.1002/cti2.1293
